Klaus Dugi
18Patents
9h-index
24Co-inventors
68Inventor score
Filing activity: Oct 31, 2006 → Apr 27, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8232281B2 | Uses of DPP-IV inhibitors | Human Necessities | 105 | Active |
| US8673927B2 | Uses of DPP-IV inhibitors | Human Necessities | 62 | Active |
| US8846695B2 | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor | Human Necessities | 45 | Active |
| US8551957B2 | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate | Human Necessities | 32 | Active |
| US8853156B2 | Treatment for diabetes in patients inappropriate for metformin therapy | Human Necessities | 28 | Active |
| US9457029B2 | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin | Human Necessities | 27 | Active |
| US9173859B2 | Uses of DPP IV inhibitors | Human Necessities | 26 | Active |
| US9486526B2 | Treatment for diabetes in patients inappropriate for metformin therapy | Human Necessities | 11 | Active |
| US10034877B2 | Treatment for diabetes in patients inappropriate for metformin therapy | Human Necessities | 11 | Active |
| US7524822B2 | Crystalline form of 1′-(1-methylethyl)-4′-[(2-fluoro-4-methoxyphenyl)methyl]-5′-methyl-1H-pyrazol-3′-O-β-D-glucopyranoside, a method for its preparation and the use thereof for preparing medicaments | Human Necessities | 8 | Active |
| US10092571B2 | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin | Human Necessities | 7 | Active |
| US8202884B2 | Treatment of type 2 diabetes | Human Necessities | 1 | Active |
| US10668074B2 | Uses of DPP IV inhibitors | General | 0 | Revoked |
| US11291668B2 | Uses of DPP IV inhibitors | Human Necessities | 0 | Active |
| US12312352B2 | Use of a DPP-4 inhibitor in SIRS and/or sepsis | Human Necessities | 0 | Active |
| US7838500B2 | Crystalline form of 1′-(1-methylethyl)-4′-[(2-fluoro-4-methoxyphenyl)methyl]-5′-methyl-1H-pyrazol-3′-O-β-D-glucopyranoside, a method for its preparation and the use thereof for preparing medicaments | Human Necessities | 0 | Active |
| US12171767B2 | Uses of DPP IV inhibitors | Human Necessities | 0 | Active |
| US10080754B2 | Uses of DPP IV inhibitors | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.